Skip to main content

Table 2 Demographics and baseline disease characteristics according to baseline SIJ inflammation and structural lesions

From: MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation

  SPARCC SIJ BME Erosion Backfill Fat metaplasia Ankylosis
≥2 n = 128 >0 n = 58 0 n = 70 >0 n = 26 0 n = 102 >0 n = 14 0 n = 114 >0 n = 3 0 n = 125
<2 n = 55 >0 n = 6 0 n = 49 >0 n = 0 0 n = 55 >0 n = 1 0 n = 54 >0 n = 1 0 n = 54
Age, years ≥2 30.0 (6.1) 33.2 (8.0) 28.9 (6.9) 32.5 (7.3) 32.3 (7.6) 31.7 (7.3) 26.3 (1.2) 31.9 (7.4)
<2 35.3 (12.4) 32.4 (8.4) 32.7 (8.8) 40.0 32.6 (8.9) 25.0 32.9 (8.9)
Male, n (%) ≥2 51 (87.9) 34 (48.6) 21 (80.8) 64 (62.8) 12 (85.7) 73 (64.0) 3 (100) 82 (65.6)
<2 3 (50.0) 22 (44.9) 25 (45.5) 1 (100) 24 (44.4) 0 25 (46.3)
BMI, kg/m2 ≥2 24.6 (3.5) 25.1 (4.5) 24.7 (3.8) 24.9 (4.2) 25.1 (3.1) 24.8 (4.2) 25.9 (4.9) 24.8 (4.1)
<2 26.7 (4.8) 25.3 (5.3) 25.4 (5.2) 30.1 25.4 (5.3) 17.3 25.6 (5.2)
Symptom duration, years ≥2 2.5 (2.3) 2.7 (1.5) 3.0 (2.9) 2.5 (1.5) 3.2 (1.7) 2.5 (1.9) 4.0 (1.2) 2.5 (1.9)
<2 2.4 (1.5) 2.0 (1.4) 2.0 (1.4) 0.3 2.0 (1.4) 4.0 2.0 (1.4)
HLA-B27 positive, n (%) ≥2 50 (86.2) 47 (67.1) 25 (96.2) 72 (70.6) 12 (85.7) 85 (74.6) 3 (100) 94 (75.2)
<2 5 (83.3) 30 (61.2) 35 (63.6) 1 (100) 34 (63.0) 1 (100) 34 (63.0)
Anterior uveitis, n (%) ≥2 5 (8.6) 8 (11.4) 1 (3.9) 12 (11.8) 2 (14.3) 11 (9.7) 1 (33.3) 12 (9.6)
<2 0 1 (2.0) 1 (1.8) 0 1 (1.9) 0 1 (1.9)
IBD, n (%) ≥2 0 0 0 0 0 0 0 0
<2 0 1 (2.0) 1 (1.8) 0 1 (1.9) 0 1 (1.9)
PsO, n (%) ≥2 6 (10.3) 12 (17.1) 2 (7.7) 16 (15.7) 3 (21.4) 15 (13.2) 0 18 (14.4)
<2 0 5 (10.2) 5 (9.1) 0 3 (5.6) 0 5 (9.3)
PsO family history, n (%) ≥2 4 (6.9) 1 (1.4) 0 5 (4.9) 1 (7.1) 4 (3.5) 0 5 (4.0)
<2 0 3 (6.1) 3 (5.5) 0 3 (5.6) 0 3 (5.6)
ASDAS-CRP ≥2 3.0 (1.1) 3.1 (0.9) 3.2 (1.1) 3.0 (1.0) 2.7 (0.7) 3.1 (1.0) 3.1 (0.1) 3.1 (1.0)
<2 2.4 (1.3) 2.8 (0.8) 2.8 (0.9) 0.7 2.8 (0.8) 1.8 2.8 (0.9)
CRP, mg/l ≥2 7.6 (9.7) 7.7 (13.9) 8.6 (9.5) 7.4 (12.8) 4.0 (4.1) 8.1 (12.8) 2.8 (2.2) 7.7 (12.3)
<2 5.8 (10.0) 4.9 (7.0) 5.0 (7.2) 1.3 5.1 (7.3) 2.2 5.1 (7.3)
BASDAI, 0–10 ≥2 5.6 (2.0) 6.4 (1.7) 5.9 (2.3) 6.1 (1.7) 5.4 (1.9) 6.1 (1.8) 6.8 (1.2) 6.0 (1.9)
<2 4.7 (2.5) 5.9 (1.6) 5.8 (1.7) 0.4 5.9 (1.6) 3.5 5.8 (1.7)
BASFI, 0–10 cm VAS ≥2 3.6 (2.6) 4.5 (2.5) 3.7 (2.8) 4.2 (2.5) 3.6 (2.0) 4.2 (2.6) 4.5 (0.7) 4.1 (2.6)
<2 3.0 (1.6) 3.9 (2.2) 3.8 (2.1) 0.5 3.8 (2.1) 2.9 3.8 (2.2)
BASMI, 0–10 ≥2 1.1 (1.3) 1.3 (1.4) 1.1 (1.5) 1.2 (1.3) 0.9 (1.1) 1.3 (1.4) 1.3 (2.2) 1.2 (1.3)
<2 1.2 (1.0) 1.4 (1.3) 1.3 (1.3) 0 1.4 (1.3) 1.3 1.3 (1.3)
SPARCC spine score, 23-DVU, 0–414 ≥2 7.5 (12.8) 4.0 (5.7) 9.1 (16.1) 4.6 (7.1) 5.6 (7.7) 5.5 (9.9) 11.7 (14.9) 5.4 (9.6)
<2 2.8 (4.2) 2.5 (3.9) 2.5 (3.9) 3.5 2.5 (3.9) 1.0 2.5 (3.9)
  1. Values are mean (standard deviation) unless stated otherwise. ASDAS-CRP Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BME bone marrow edema, BMI body mass index, CRP C-reactive protein, DVU discovertebral units, HLA human leukocyte antigen, IBD inflammatory bowel disease, PsO psoriasis, SIJ sacroiliac joint, SPARCC Spondyloarthritis Research Consortium of Canada, VAS visual analog scale